PAREXEL International excels in pharmaceutical development services. A top contract research organization (CRO), the firm counts among its clients some of the world's largest drug, biotech, diagnostics, and medical device firms. Its core Clinical Research Services (CRS) segment provides clinical trial and data management, study design, patient recruitment, biostatistical analysis, clinical pharmacology, and industry training and publishing. Its PAREXEL Consulting Services (PC) segment handles the non-clinical aspects of drug development, regulatory affairs, and new product launches. Finally, the PAREXEL Informatics (PI) segment offers patient technology solutions and regulatory and clinical solutions. PAREXEL was taken private by Pamplona Capital Management for $4.5 billion in 2017.
See detailed business credit reports on other businesses or your own.
See detailed profiles for insights and prospects on this company's top competitors.
Essential information for a successful call
EMPLOYEES (This Site)
EMPLOYEES (All Sites)
REVENUE (MIL USD)
- Incorporated 2017
- FISCAL YEAR END JUN
Get in Touch with 917 Contacts and 8 Principals*
Josef von RickenbachChief Executive Officer
MARK A GOLDBERGPresident and Chief Operating Officer
SIMON HARFORDSenior Vice President and Chief Financial Officer
MICHELLE GRAHAMSenior Vice President and Officer